Attention Deficit Hyperactivity Disorder. Hyperkinetic disorders
Conditions
Interventions
Intervention 1: The intervention group consume 1000 IU Vitamin D3 supplementation daily in during12 weeks. Intervention 2: The control group consume Plasebo daily in during12 weeks intervention.
Treatment - Other
Placebo
The intervention group consume 1000 IU Vitamin D3 supplementation daily in during12 weeks.
The control group consume Plasebo daily in during12 weeks intervention.
Sponsors
Vice chancellor for research Isfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
6 Years to 13 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age group participants is 6-13 years; Non-having other chronic diseases; Lack of consumption of Vitamin D supplementation from two months before the intervention; Lack of consumption of Selenium, Calcium, Vitamin C ,Vitamin E, Omega3 and Zinc supplementations from one month before the intervention. Exclusion criteria: The use of methods such as neurofeedback, play-therapy and parenting education during the intervention; nonconsent of parents for the continued cooperation During the study .
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 25(OH)Vitamin D3. Timepoint: before entering to the study and 12 weeks after Vitamin D or placebo consumption. Method of measurement: serum level measurement.;Attention. Timepoint: before entering to the study and 12 weeks after Vitamin D or placebo consumption. Method of measurement: continue performance test score.;Impulsive. Timepoint: before entering to the study and 12 weeks after Vitamin D or placebo consumption. Method of measurement: continue performance test score.;Behaviral disorder. Timepoint: before entering to the study and 12 weeks after Vitamin D or placebo consumption. Method of measurement: Strengths and Difficulties Questionnaire score.;Antioxidant Capacity of serum. Timepoint: before entering to the study and 12 weeks after Vitamin D or placebo consumption. Method of measurement: serum level measurement. | — |
Secondary
| Measure | Time frame |
|---|---|
| Body Mass Index. Timepoint: before entering to the study and 12 weeks after vitamin D or Placebo consumption. Method of measurement: Digital scale and meter.;Food receives. Timepoint: before entering to the study & 12 weeks after drug or placebo consumption. Method of measurement: Food record. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Amir Mansour Alavi Naiini
Isfahan University of Medical Sciences, School of Nutrition and Food Sciences
Outcome results
None listed